CION Ameerpet
Ovarian cancer is far more common after menopause than before it — most diagnoses are made in women over 50, and the risk keeps climbing into the seventies. But it is not only a disease of older women, and being young is not the same as being immune. What age mostly changes is which kind of ovarian tumour is likely, and how a finding on a scan should be read.
Ovarian cancer can occur at almost any age, from the teenage years onwards. It is not, however, spread evenly across a life. Risk is low through the twenties and thirties, begins to climb from the mid-forties, and is highest after menopause — most women diagnosed with the commonest form are over 50, and incidence keeps rising into the seventies before it flattens.
The ovarian cancer age figures you find online come almost entirely from large Western registries, and they describe populations rather than people. What they capture reliably is the shape of the curve, not your own risk. For how the disease behaves closer to home, see how common ovarian cancer is in India.
Exactly what age ovarian cancer becomes a realistic concern depends less on a birthday than on two other things: whether you carry an inherited risk, and whether you have a symptom or a scan finding that needs explaining. A BRCA variant shifts the whole curve about a decade earlier. And a symptom that has persisted for weeks deserves the same attention at 28 as at 68 — what differs is what the answer usually turns out to be.
Incidence climbs from the mid-forties and peaks after menopause. The commonest type is largely a post-menopausal disease.
Ovarian cancer does occur in the teens and twenties. It is uncommon there, and the types seen at that age are usually far more treatable.
It does not change what deserves checking. A new, persistent symptom is worth explaining at any age.
The median age at diagnosis of ovarian cancer is 63, and age-specific incidence is highest in women in their late fifties and sixties, easing only in very old age. About one diagnosis in eight is made before the age of 45. That difference is exactly why a new ovarian cyst in a woman who has been through menopause is looked at more carefully than the same cyst at 30 — by then the ovary should be quiet, and it is not. Source: National Cancer Institute, SEER Cancer Stat Facts: Ovarian Cancer.
Age does not only change how likely ovarian cancer is. It changes which type is likely, how it tends to present, and what a mass on a scan usually turns out to be.
| Age band | What an ovarian tumour usually is | What that means in practice |
|---|---|---|
| Under 20 | Ovarian cancer is very rare. When it does occur it is usually a germ cell tumour rather than the epithelial type seen in adults. | Germ cell tumours respond strongly to chemotherapy, are often curable, and can frequently be treated while preserving fertility. |
| 20–39 | Most ovarian masses are functional cysts, dermoids or endometriomas. Cancer is uncommon; germ cell and borderline tumours account for much of it. | The blood tests differ — germ cell markers matter here as much as CA-125. See ovarian cancer in young women and teenagers. |
| 40–49 | The transition decade. Borderline and low-grade tumours are relatively more common than they will be later, and invasive epithelial cancer starts to appear. | CA-125 is at its least reliable here, because fibroids, endometriosis and menstruation itself can raise it. |
| 50–64 | The peak years for high-grade serous carcinoma, the commonest and most aggressive epithelial type. | Any new ovarian cyst after menopause is characterised properly. The post-menopausal ovary should be quiescent. |
| 65+ | Incidence stays high. High-grade serous still dominates, and disease is more often advanced when it is found. | Fitness for treatment, rather than age itself, should decide what is offered. Older women are frequently under-treated on age alone. |
*A general pattern, not a rule. Every one of these tumour types has been reported outside its usual age band, which is why a finding is judged on its own features rather than on your date of birth.
Age is not simply a risk number. It quietly alters how each test is read, and what a normal result is worth.
The leading explanation is that most high-grade serous cancers do not begin in the ovary at all. They begin in the lining of the fallopian tube, in cells that accumulate genetic damage over decades — including changes in the TP53 gene, which are present in the earliest recognised precursor lesions. Damage that builds up slowly fits a curve that rises with age.
Reproductive history contributes in the same direction. Early menarche, late menopause and never having been pregnant all mean more ovulatory cycles across a lifetime, and each cycle involves rupture and repair of the ovarian surface. None of this is deterministic: the great majority of women who reach 70 never develop ovarian cancer.
A BRCA1 or BRCA2 pathogenic variant does not simply raise lifetime risk — it brings it forward. Ovarian cancer in BRCA1 carriers typically appears earlier than in BRCA2 carriers, and both appear earlier than in the general population. Lynch syndrome does something similar. This is the single most useful thing to know about your own age and risk, and it is knowable.
It is also why guidelines tie risk-reducing surgery to an age rather than to symptoms: NCCN advises discussing risk-reducing removal of the tubes and ovaries typically between 35 and 40 for BRCA1 and 40 to 45 for BRCA2, once childbearing is complete. Genetic counselling, BRCA testing and HRD testing are delivered in-house at CION.
CA-125 is not a cancer test. It is a protein that rises in many ordinary conditions, and most of those conditions belong to younger women: endometriosis, fibroids, pelvic infection, pregnancy, and menstruation itself. A mildly raised CA-125 in a 34-year-old with endometriosis is close to expected. The same number in a 66-year-old with a complex cyst means something quite different.
The scoring systems build this in openly. The ROMA score uses separate pre- and post-menopausal cut-offs, and the risk of malignancy index multiplies the CA-125 value by a menopausal-status factor. The reverse trap applies at every age: a normal CA-125 does not exclude ovarian cancer, particularly in early-stage and in some non-serous subtypes.
Before menopause the ovaries make cysts as part of normal function. A simple, thin-walled, fluid-filled cyst in a woman of 30 is usually physiological, and the standard response is to re-scan after a couple of cycles rather than to operate — most have gone by then.
After menopause that reasoning no longer holds, because the ovary should have stopped cycling. A new cyst is therefore characterised properly the first time: its wall, any solid areas, septations and blood flow are all assessed and combined with CA-125. Even then, most simple post-menopausal cysts turn out to be benign. The point is not alarm, it is that nothing is assumed to be functional.
Older women with ovarian cancer are consistently offered less treatment than younger women with the same disease, and not always for good reasons. Where the reason is genuine frailty, poor kidney or heart function, or significant other illness, adjusting treatment is correct and often kinder. Where the reason is the number on a birth certificate, it is not.
The useful assessment is performance status, organ function, nutrition and what support exists at home. Many women in their seventies complete standard treatment well. At CION, chemotherapy and maintenance therapy are delivered in-house across 35+ centres, while ovarian surgery is coordinated with specialist gynaecologic-oncology partner centres and may be billed there. See ovarian cancer treatment in Hyderabad.
There is no effective screening test for ovarian cancer at any age — not for women in their sixties, and not for BRCA carriers either. UKCTOCS, the largest ovarian cancer screening trial ever run, followed more than 200,000 post-menopausal women and reported in 2021 that annual screening with CA-125 and ultrasound did not reduce deaths from ovarian cancer.
That is worth stating plainly, because a yearly CA-125 is often sold as reassurance and it does not earn the name. Surveillance in high-risk women is offered while a decision about risk-reducing surgery is being made, not as protection. What actually finds ovarian cancer earlier is a woman noticing a persistent change and a clinician taking it seriously.
None of these means cancer. Each is a reason to be examined and scanned rather than reassured over the phone.
New, persistent and not settling — more than 12 days in a month is the pattern that matters, whatever your age.
A real change in how much you can eat, rather than the occasional heavy meal.
The post-menopausal ovary should be quiet. Most such cysts are still benign, but they are characterised rather than assumed.
Clothes tightening at the waist while the scales fall is a combination that needs explaining quickly.
Ovarian, breast, bowel or endometrial cancer in close relatives, especially diagnosed young, is a reason to ask about genetic testing.
Torsion or rupture of a cyst is an emergency at any age, and is commonest in younger women. Same-day assessment.
If you are under 40 the odds are strongly in your favour and the likeliest explanations are benign — but a symptom that has run for weeks still deserves an examination and a scan. Being young is a reason to expect a reassuring answer, not a reason to skip the question.
A symptom that has persisted for weeks, or an ovarian finding on a scan, deserves the same look at 28 as at 68. What changes is how the result is interpreted, not whether it is worth asking.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Chemotherapy, maintenance therapy, genetic counselling and BRCA testing are delivered in-house at CION across 35+ centres.
The sequence is the same at every age. What changes is which tests carry weight, and how the numbers are read once they come back.
How long the symptoms have run, family history on both sides of the family, periods and menopausal status. Menopausal status is not a formality here — it feeds directly into how the next two tests are scored.
Transvaginal and transabdominal. In a younger woman a simple cyst is usually physiological and is often re-scanned after a couple of cycles; after menopause a new cyst is characterised properly at the first visit.
CA-125 in everyone, read against menopausal status. Under about 40, germ cell markers are added, because the tumours seen at that age produce different proteins. HE4 and the ROMA score apply separate pre- and post-menopausal cut-offs.
Ultrasound features, marker levels and menopausal status are combined rather than read in isolation — the risk of malignancy index does this explicitly. A CT scan of the abdomen and pelvis follows where the combination is concerning.
Where the picture suggests malignancy, care belongs with a gynaecologic-oncology team. At CION, chemotherapy, maintenance therapy and genetic testing are delivered in-house, while ovarian surgery is coordinated with specialist gynaecologic-oncology partner centres and may be billed there.
*No single result decides anything. A raised CA-125 in a 35-year-old with endometriosis and the same value in a 65-year-old with a complex cyst are not the same finding.
Younger women do appear to do better in published series — but the reason is mostly not youth itself. It is that the cancers diagnosed at younger ages are different cancers: more germ cell tumours, more borderline tumours, more low-grade and early-stage disease. Compare like with like, the same subtype at the same stage, and much of the gap closes.
The rest of the explanation is treatment. Older women are more likely to have other illnesses, more likely to be offered a reduced plan, and less likely to be entered into trials. Where an older woman is fit, her outlook follows her disease rather than her age. Performance status, kidney and heart function, nutrition and support at home are the questions worth asking — not the year she was born.
This is also why age-banded survival figures mislead. They are historical, they average every subtype and stage together, and they mix women who had complete surgery with women who did not. CION publishes its own one-year survival alongside the national figure so that the comparison is at least visible: 81.0% of CION ovarian cancer patients are alive at one year, against a national figure of 73.7%. That is a one-year figure across all ages and stages — not a cure rate, and not a prediction for any individual.
CION ovarian cancer patients alive at one year from diagnosis. *One-year survival, CION treated population, all stages.
The comparable national figure. *One-year survival; national registry data, all stages.
Younger women more often have germ cell, borderline and low-grade tumours, which behave differently from high-grade serous.
Organ function and performance status decide what treatment is safe. Age alone is a poor reason to offer less.
*One-year survival rates across all stages. CION figures reflect CION's treated patient population; national figures are drawn from published Indian cancer registry data. Survival statistics describe groups rather than individuals — discuss your own outlook with your treating oncologist.
Two very different women read a page like this. One is 29, has had bloating for a month, and has been told twice that it is probably her diet. The other is 64, has a cyst reported on a scan done for something else, and has been given a follow-up appointment in three months with no explanation of what is being watched for. Both deserve a straight answer, and neither needs a referral to get one.
Your first consultation at CION is free and runs to about 45 minutes. Bring any scan reports, blood results and a rough family history on both sides — who had which cancer, and at what age, because the age of a relative's diagnosis often matters more than the number of relatives. Most of the useful work is deciding what the finding actually is, what the next test should be, and whether genetic testing belongs in the conversation.
The division of work should be clear from the start. Chemotherapy, maintenance therapy, genetic counselling, BRCA and HRD testing, nutrition support and long-term follow-up are delivered in-house at CION across 35+ centres in Telangana and Andhra Pradesh. Ovarian surgery, including staging, debulking and fertility-sparing surgery, is coordinated with specialist gynaecologic-oncology partner centres and may be billed there — arranged that way because specialist surgery genuinely changes outcomes in this disease. Every case is reviewed by a tumour board. For the wider picture, start with the complete ovarian cancer guide.
Free and unhurried, whether you are 25 with a cyst or 70 with a new diagnosis. No referral needed.
Medical oncology, pathology and imaging review the plan together before anything is settled.
Ovarian surgery is carried out at specialist partner centres and may be billed there. Said upfront, not discovered later.
CION patients on the supported nutrition pathway — which matters most for older women, where nutrition often decides tolerance.
Most often, women after menopause. Incidence is low through the twenties and thirties, begins to climb from the mid-forties, and is highest in the late fifties and sixties, with the median age at diagnosis around 63. Roughly one diagnosis in eight is made before 45. That said, the disease occurs across the whole adult lifespan, and the type varies with age: germ cell tumours in the teens and twenties, borderline and low-grade tumours relatively more often in the thirties and forties, and high-grade serous carcinoma dominating after 50. An inherited BRCA1 or BRCA2 variant brings the whole pattern forward by roughly a decade, which is why family history matters more than a birthday.
Yes, though it is uncommon. Most ovarian masses at that age are functional cysts, dermoids or endometriomas, and the great majority are benign. When cancer does occur under 40 it is more often a germ cell tumour or a borderline tumour than the high-grade serous type seen after menopause — and those tend to respond very well to treatment, often with fertility preserved. The practical point is that a persistent symptom in a young woman still deserves an examination and a scan. Being young makes a reassuring answer far more likely; it is not a reason to skip the question. Our guide to ovarian cancer in young women and teenagers covers this age group in detail.
Predominantly of older women, but not exclusively. The commonest form, high-grade serous carcinoma, is largely a post-menopausal disease, and incidence keeps rising into the seventies. The tumours that affect young women are a different group altogether — germ cell tumours, sex cord-stromal tumours and borderline tumours — which is why the answer sounds contradictory depending on which type is being discussed. So both statements are true: ovarian cancer mostly affects women over 50, and ovarian cancer can affect a teenager. What follows from that is practical, not reassuring or alarming: age changes what a finding most likely is, and therefore which tests are chosen, but not whether a persistent symptom should be assessed.
No. The pattern is the same at 25 and at 75: bloating that is new and persists on most days, feeling full quickly, pelvic or abdominal pain that does not settle, and passing urine more often or more urgently. What age changes is how likely those symptoms are to be caused by cancer, and what else is competing to explain them. In a younger woman, irritable bowel syndrome, endometriosis and functional cysts are far commoner explanations. After menopause, the same symptoms carry more weight simply because the alternatives are fewer. Persistence is the signal at every age — a symptom that is new for you and has run for three weeks or more warrants an examination rather than a phone call.
No. Most cysts found after menopause are still benign — simple, thin-walled, fluid-filled cysts particularly so. What age changes is that nothing is assumed to be functional. Before menopause the ovaries routinely make cysts as part of normal cycling, so a simple cyst is often just re-scanned after a couple of cycles. After menopause the ovary should be quiescent, so a new cyst is characterised properly the first time: its wall, any solid areas, septations and blood flow are assessed on ultrasound and combined with CA-125 and your menopausal status. Ask what the ultrasound features actually were and what the follow-up plan is watching for — those two answers usually settle the anxiety.
There is no effective screening test for ovarian cancer, at any age, and that includes women who carry a BRCA variant. UKCTOCS, the largest screening trial ever conducted, followed more than 200,000 post-menopausal women and reported in 2021 that annual CA-125 and ultrasound screening did not reduce deaths from ovarian cancer. A yearly CA-125 is often offered as reassurance, and it does not deserve that role. For women at high inherited risk, surveillance is sometimes used while a decision about risk-reducing removal of the tubes and ovaries is being made — as a holding measure, not as protection. Genetic counselling and BRCA testing are delivered in-house at CION, and are far more useful than any screening blood test.
The first consultation is free and runs to about 45 minutes, with no referral needed — bring any scan reports, blood results and a family history noting the age at which relatives were diagnosed. Chemotherapy and maintenance therapy are delivered in-house at CION across more than 35 centres in Telangana and Andhra Pradesh, as are genetic counselling, BRCA and HRD testing, nutrition support and long-term follow-up, where patients on the supported nutrition pathway experience 67% less weight loss during treatment. Ovarian surgery, including staging, debulking and fertility-sparing surgery, is coordinated with specialist gynaecologic-oncology partner centres and may be billed there. Treatment decisions rest on fitness, organ function and disease, not on age alone, and every case is reviewed by a tumour board.